Multi-Institutional Analysis of Early Glottic Cancer from 2000 to 2005

Radiation Oncology

Yasunori Obata²  Masahiro Sasaoka⁹  Yoshimi Horikawa⁵  Yoshihito Nomoto⁴  Akiko Asano⁷  Takayuki Murao³  Kazuyuki Koyama¹  Kazunori Suzuki⁸  Shunichi Ishihara⁶  Shinji Naganawa⁶  Yoshiyuki Itoh⁶  Naoki Hirasawa⁶ 

[1] Department of Radiology, Tajimi Prefectural Hospital, 5-161 Maebata-cho, Tajimi, Gifu, 507-8522, Japan;Department of Radiological Technology, Nagoya University Graduate School of Medicine, 1-1-20 Daikou-minami, Higashi-ku, Nagoya, Aichi, 461-8673, Japan;Department of Radiology, Ichinomiya Municipal Hospital, 2-2-22 Bunkyo, Ichinomiya, Aichi, 491-8558, Japan;Department of Radiology, Mie University School of Medicine, 2-174 Edobashi, Tsu, Mie, 514-8507, Japan;Department of Radiology, Kainan Hospital, 396 Minami-honden, Maegasu-cho, Yatomi, Aichi, 498-8502, Japan;Department of Radiology, Nagoya University Graduate School of Medicine, 65 Tsurumai-cho, Shouwa-ku, Nagoya, Aichi, 466-8550, Japan;Department of Radiology, Toyohashi Municipal Hospital, 50 Hachiken Nishi, Aotake-cho, Toyohashi, Aichi, 441-8570, Japan;Department of Radiology, Hamamatsu University School of Medicine, 1-20-1 Handayama, higashi-ku, Hamamatsu, Shizuoka, 431-3192, Japan;Department of Radiology, Ise Municipal General Hospital, 3038 Kusube-cho, Ise, Mie, 516-0014, Japan

关键词: Outcomes;    Multiple institutes;    Chemoradiotherapy;    Glottic cancer;    Radiotherapy;   

Others  :  1228574
DOI  :  10.1186/1748-717X-7-122

 received in 2012-04-11, accepted in 2012-07-25,  发布年份 2012

【 摘 要 】

Background

The purpose of this study is to analyze the outcome of patients with early glottic cancer (GC) treated with radiotherapy (RT) with or without chemotherapy at 10 institutions in the Tokai District, Japan.

Methods

Ten institutions combined data from 279 patients with T1-T2 GC treated with RT with or without chemotherapy between 2000 and 2005. The overall survival rate, disease-specific survival rate, and local control rate were evaluated in 270 patients, except for incomplete cases due to issues such as discontinuation, using the method of Kaplan-Meier and compared using the log-rank test. Results were considered statistically significant at the level of p < 0.05.

Results

For 122 patients, the tumors were classified as T1a, while 64 patients had T1b tumors, and 84 patients had T2 tumors. In three cases of T1 tumors, the subtype was unknown. Combined chemoradiotherapy (CRT) was administered during each stage, and various chemotherapy drugs and regimens were used. The median follow-up period was 55.4 months. The 5-year LC rates for T1a, Tb, and T2 tumors in all patients were 87.9%, 82.7%, and 74.1%, respectively. The difference between T1a and T2 was statistically significant (p = 0.016). The 5-year LC rates for T1a, Tb, and T2 with CRT were 92.7%, 78.6%, and 80.7%, respectively, while the rates with radiation alone were 86.5%, 83.8%, and 64.4%, respectively. The difference between CRT and RT alone was not statistically significant in each stage.

Conclusions

In this survey, CRT was performed for early GC at most institutions in clinical practice. Our data showed no statistical difference in the LC rates between CRT and RT alone in each stage. However, there was a tendency for the LCRs of the CRT group to be more favorable than those of the RT group in the T2-stage.

【 授权许可】

   
2012 Hirasawa et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1 .

Figure 2 .

Figure 3 .

【 参考文献 】

• [1]Wendt TG, Grabenbauer GG, Rodel CM, Thiel HJ, Aydin H, Rohloff R, Wustrow TP, Iro H, Popella C, Schalhorn A: Simultaneous radiochemotherapy versus radiotherapy alone in advanced head and neck cancer: a randomized multicenter study. J Clin Oncol 1998, 16:1318-1324.
• [2]Calais G, Alfonsi M, Bardet E, Sire C, Germain T, Bergerot P, Rhein B, Tortochaux J, Oudinot P, Bertrand P: Randomized trial of radiation therapy versus concomitant chemotherapy and radiation therapy for advanced-stage oropharynx carcinoma. J Natl Cancer Inst 1999, 91:2081-2086.
• [3]Adelstein DJ, Lavertu P, Saxton JP, Secic M, Wood BG, Wanamaker JR, Eliachar I, Strome M, Larto MA: Mature results of a phase III randomized trial comparing concurrent chemoradiotherapy with radiation therapy alone in patients with stage III and IV squamous cell carcinoma of the head and neck. Cancer 2000, 88:876-883.
• [4]Pignon JP, Bourhis J, Domenge C, Designe L: Chemotherapy added to locoregional treatment for head and neck squamous-cell carcinoma: three meta-analyses of updated individual data. MACH-NC Collaborative Group. Meta-Analysis of Chemotherapy on Head and Neck Cancer. Lancet 2000, 355:949-955.
• [5]Forastiere AA, Goepfert H, Maor M, Pajak TF, Weber R, Morrison W, Glisson B, Trotti A, Ridge JA, Chao C, et al.: Concurrent chemotherapy and radiotherapy for organ preservation in advanced laryngeal cancer. N Engl J Med 2003, 349:2091-2098.
• [6]Garden AS, Morrison WH, Ang KK: Larynx and hypopharynx cancer. In Clinical Radiation Oncology. 2nd edition. Edited by Gunderson LL, Tepper JE. Churchill Livingstone, Elsevier, Philadelphia; 2007:727-753.
• [7]Mendenhall WM, Hinerman RW, Amdur RJ, Mancuso AA, Villaret DB, Werning JW: Larynx. In Perez and Brady’s Principles and Practice of Radiation Oncology. 5th edition. Edited by Halperin EC, Perez CA, Brady LW. Lippincott William & Wilkins, Philadelphia; 2008:975-995.
• [8]Mendenhall WM, Amdur RJ, Morris CG, Hinerman RW: T1-T2N0 squamous cell carcinoma of the glottic larynx treated with radiation therapy. J Clin Oncol 2001, 19:4029-4036.
• [9]Jin J, Liao Z, Gao L, Huang X, Xu G: Analysis of prognostic factors for T(1)N(0)M(0) glottic cancer treated with definitive radiotherapy alone: experience of the cancer hospital of Peking Union Medical College and the Chinese Academy Of Medical Sciences. Int J Radiat Oncol Biol Phys 2002, 54:471-478.
• [10]Dinshaw KA, Sharma V, Agarwal JP, Ghosh S, Havaldar R: Radiation therapy in T1-T2 glottic carcinoma: influence of various treatment parameters on local control/complications. Int J Radiat Oncol Biol Phys 2000, 48:723-735.
• [11]Nomiya T, Nemoto K, Wada H, Takai Y, Yamada S: Long term results of radiotherapy for T1a and T1bN0M0 glottic carcinoma. Laryngoscope 2008, 118:1417-14211.
• [12]Cellai E, Frata P, Magrini SM, Paiar F, Barca R, Fondelli S, Polli C, Livi L, Bonetti B, Vitali E: Radical radiotherapy for early glottic cancer: Results in a series of 1087 patients from two Italian radiation oncology centers. I. The case of T1N0 disease. Int J Radiat Oncol Biol Phys 2005, 63:1378-1386.
• [13]Frata P, Cellai E, Magrini SM, Bonetti B, Vitali E, Tonoli S, Buglione M, Paiar F, Barca R, Fondelli S: Radical radiotherapy for early glottic cancer: Results in a series of 1087 patients from two Italian radiation oncology centers. II. The case of T2N0 disease. Int J Radiat Oncol Biol Phys 2005, 63:1387-1394.
• [14]Reddy SP, Hong RL, Nagda S, Emami B: Effect of tumor bulk on local control and survival of patients with T1 glottic cancer: a 30-year experience. Int J Radiat Oncol Biol Phys 2007, 69:1389-1394.
• [15]Narayana A, Vaughan AT, Kathuria S, Fisher SG, Walter SA, Reddy SP: P53 overexpression is associated with bulky tumor and poor local control in T1 glottic cancer. Int J Radiat Oncol Biol Phys 2000, 46:21-26.
• [16]National Comprehensive Cancer Network clinical practice guidelines in oncology, Head and Neck Cancers v.2.2010 http://wwwnccnorg/professionals/physician_gls/f_guidelinesasp webcite
• [17]Pfister DG, Laurie SA, Weinstein GS, Mendenhall WM, Adelstein DJ, Ang KK, Clayman GL, Fisher SG, Forastiere AA, Harrison LB, et al.: American Society of Clinical Oncology clinical practice guideline for the use of larynx-preservation strategies in the treatment of laryngeal cancer. J Clin Oncol 2006, 24:3693-3704.
• [18]Hirasawa N, Itoh Y, Naganawa S, Ishihara S, Suzuki K, Nomoto Y, Murao T, Horikawa Y, Koyama K, Sasaoka M, et al.: The results of 29 respondent otolaryngologists to questionnaires for strategy of early glottic cancer. Jpn J Clin Radiol 2010, 55:541-546.
• [19]Itoh Y, Hirasawa N, Naganawa S, Ishihara S, Suzuki K, Koyama K, Murao T, Asano A, Nomoto Y, Horikawa Y, et al.: Combined chemoradiotherapy for early glottic cancer in clinical practice in Japan: analysis of 10 institutions. Anticancer Res 2010, 30:5181-5184.
• [20]Furusaka T, Matuda H, Saito T, Katsura Y, Ikeda M: Long-term observations and salvage operations on patients with T2N0M0 squamous cell carcinoma of the glottis larynx treated with radiation alone. Acta Otolaryngol 2012, 132:546-551.
• [21]Akimoto T, Nonaka T, Kitamoto Y, Ishikawa H, Ninomiya H, Chikamatsu K, Furuya N, Hayakawa K, Mitsuhashi N, Nakano T: Radiation therapy for T2N0 laryngeal cancer: A retrospective analysis for the impact of concurrent chemotherapy on local control. Int J Radiat Oncol Biol Phys 2006, 64:995-1001.
• [22]Itoh Y, Fuwa N: Retrospective analysis: concurrent chemoradiotherapy using protracted continuous infusion of low-dose cisplatin and 5-fluorouracil for T2N0 glottic cancer. Radiat Med 2006, 24:277-281.
• [23]Kumamoto Y, Masuda M, Kuratomi Y, Toh S, Shinokuma A, Chujo K, Yamamoto T, Komiyama S: "FAR" chemoradiotherapy improves laryngeal preservation rates in patients with T2N0 glottic carcinoma. Head Neck 2002, 24:637-642.
• [24]Tsuji H, Kiba T, Nagata M, Inoue T, Yukawa H, Yamashita T, Shimode Y, Murata H, Nagata K, Tomoda K: A phase I study of concurrent chemoradiotherapy with S-1 for T2N0 glottic carcinoma. Oncology 2006, 71:369-373.
• [25]Niibe Y, Nakayama M, Matsubayashi T, Takahashi H, Kitano M, Okamoto M, Hayakawa K: Effectiveness of concurrent radiation therapy with UFT or TS-1 for T2N0 glottic cancer in Japan. Anticancer Res 2007, 27:3497-3500.
• [26]Hirasawa N, Itoh Y, Ishihara S, Kubota S, Itoh J, Fujimoto Y, Nakashima T, Naganawa S: Radiotherapy with or without chemotherapy for patients with T1-T2 glottic carcinoma: retrospective analysis. Head Neck Oncol 2010, 2:20. BioMed Central Full Text
• [27]Yamazaki H, Nishiyama K, Tanaka E, Koizumi M, Chatani M: Radiotherapy for early glottic carcinoma (T1N0M0): results of prospective randomized study of radiation fraction size and overall treatment time. Int J Radiat Oncol Biol Phys 2006, 64:77-82.
• [28]Nomiya T, Nemoto K, Wada H, Takai Y, Yamada S: Advantage of accelerated fractionation regimens in definitive radiotherapy for stage II glottis caricinoma. Ann Otol Rhinol Laryngol 2006, 115:727-732.
• [29]Haugen H, Johansson KA, Mercke C: Hyperfractionated-accelerated or conventionally fractionated radiotherapy for early glottic cancer. Int J Radiat Oncol Biol Phys 2002, 52:109-119.
• [30]Garden AS, Forster K, Wong PF, Morrison WH, Schechter NR, Ang KK: Results of radiotherapy for T2N0 glottic carcinoma: does the "2" stand for twice-daily treatment? Int J Radiat Oncol Biol Phys 2003, 55:322-328.
• [31]Trotti A, Pajak T, Emami B, Hammond E, Jones C, Morrison W, Sagar S, Ridge J, Fu KK, Ang K: A Randomized Trial of Hyperfractionation Versus Standard Fractionation In T2 Squamous Cell Carcinoma of The Vocal Cord. Int J Radiat Oncol Biol Phys 2006, 66(1):S15.
• [32]Chera BS, Amdur RJ, Morris CG, Kirwan JM, Mendenhall WM: T1N0 to T2N0 squamous cell carcinoma of the glottic larynx treated with definitive radiotherapy. Int J Radiat Oncol Biol Phys 2010, 78:461-466.
• [33]Jones DA, Mendenhall CM, Kirwan J, Morris CG, Donnan A, Holwerda S, Kraus ST, Mann CJ, Grant JR, Donnan B, Mendenhall WM: Radiation therapy for management of T1-T2 glottic cancer at a private practice. Am J Clin Oncol 2010, 33:587-590.